Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, 4D Molecular Therapeutics Inc’s stock clocked out at $8.32, down -0.95% from its previous closing price of $8.4. In other words, the price has decreased by -$0.95 from its previous closing price. On the day, 0.57 million shares were traded. FDMT stock price reached its highest trading level at $8.45 during the session, while it also had its lowest trading level at $8.1101.
Ratios:
To gain a deeper understanding of FDMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.75 and its Current Ratio is at 8.75. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on January 13, 2025, Downgraded its rating to Market Perform and sets its target price to $15 from $40 previously.
On November 21, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 23 ’25 when Bizily Scott sold 2,407 shares for $8.00 per share. The transaction valued at 19,256 led to the insider holds 7,596 shares of the business.
SCOTT BIZILY bought 7,312 shares of FDMT for $54,109 on Sep 23 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 392300704 and an Enterprise Value of 118416528. For the stock, the TTM Price-to-Sale (P/S) ratio is 12952.13 while its Price-to-Book (P/B) ratio in mrq is 0.92. Its current Enterprise Value per Revenue stands at 3588.38 whereas that against EBITDA is -0.549.
Stock Price History:
The Beta on a monthly basis for FDMT is 2.92, which has changed by -0.07555556 over the last 52 weeks, in comparison to a change of 0.15927899 over the same period for the S&P500. Over the past 52 weeks, FDMT has reached a high of $9.96, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is 21.42%, while the 200-Day Moving Average is calculated to be 70.19%.
Shares Statistics:
It appears that FDMT traded 1.15M shares on average per day over the past three months and 622140 shares per day over the past ten days. A total of 46.70M shares are outstanding, with a floating share count of 42.62M. Insiders hold about 8.75% of the company’s shares, while institutions hold 81.98% stake in the company. Shares short for FDMT as of 1757894400 were 4691697 with a Short Ratio of 4.09, compared to 1755216000 on 4142441. Therefore, it implies a Short% of Shares Outstanding of 4691697 and a Short% of Float of 10.459999999999999.
Earnings Estimates
. The current rating of 4D Molecular Therapeutics Inc (FDMT) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.46 and low estimates of -$1.1.
Analysts are recommending an EPS of between -$3.19 and -$3.98 for the fiscal current year, implying an average EPS of -$3.69. EPS for the following year is -$3.81, with 9.0 analysts recommending between -$2.8 and -$4.76.
